LSTA - LISATA THERAPEUTICS, INC.
IEX Last Trade
2.77
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:58:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.77
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.48%
1 Month
8.98%
3 Months
8.60%
6 Months
-9.24%
1 Year
8.22%
2 Year
22.69%
Key data
Stock price
$2.77
DAY RANGE
$2.77 - $2.99
52 WEEK RANGE
$2.66 - $3.83
52 WEEK CHANGE
$9.75
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: David J. Mazzo
Region: US
Website: caladrius.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: caladrius.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.
Recent news